Osteoarthritis – Pipeline Review, H1 2017, provides an overview of the Osteoarthritis (Immunology) pipeline landscape.
Osteoarthritis (OA) is one of the most common forms of arthritis. It is a chronic condition in which the cartilage breaks down. Symptoms of osteoarthritis include sore or stiff joints, pain that is worse after activity, bone spurs and grating sensation. Risk factors include older age, joint injuries and obesity. Treatment includes surgery, medications like non-steroidal anti-inflammatory drugs (NSAIDs) and exercise.
Request a sample of this report @ http://www.orbisresearch.com/contacts/request-sample/224948 .
Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Osteoarthritis – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Osteoarthritis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Osteoarthritis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Osteoarthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 7, 21, 14, 46 and 14 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 5 molecules, respectively.
Osteoarthritis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Browse the full report @ http://www.orbisresearch.com/reports/index/osteogenesis-imperfecta-pipeline-review-h1-2017 .
– The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoarthritis (Immunology).
– The pipeline guide reviews pipeline therapeutics for Osteoarthritis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Osteoarthritis (Immunology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Osteoarthritis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Osteoarthritis (Immunology)
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Osteoarthritis (Immunology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Osteoarthritis (Immunology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Purchase a copy of this report @ http://www.orbisresearch.com/contact/purchase/224948 .
A. Menarini Industrie Farmaceutiche Riunite Srl
Abiogen Pharma SpA
Achelios Therapeutics Inc
Addex Therapeutics Ltd
Amura Holdings Ltd
Asahi Kasei Pharma Corp
Asklepios BioPharmaceutical Inc
Astellas Pharma Inc
Bone Therapeutics SA
Can-Fite BioPharma Ltd
Cellular Biomedicine Group Inc
Dong-A Socio Holdings Co Ltd
Evgen Pharma Plc
F. Hoffmann-La Roche Ltd
Gemphire Therapeutics Inc
Genequine Biotherapeutics GmbH
InKemia IUCT Group SA
International Stem Cell Corp
Jeil Pharmaceutical Co Ltd
Jenrin Discovery Inc
K-Stemcell Co Ltd
Kang Stem Biotech Co Ltd
Levolta Pharmaceuticals Inc
LG Chem, Ltd.
Marina Biotech Inc
Mor Research Application Ltd
Nordic Bioscience A/S
NovelMed Therapeutics Inc
Ono Pharmaceutical Co Ltd
Osteologix Holdings Plc
PLx Pharma Inc
Rottapharm Biotech Srl
Stelis Biopharma Pvt Ltd
Takeda Pharmaceutical Company Ltd
Yooyoung Pharmaceutical Co Ltd
Yungjin Pharm Co Ltd
Zimmer Biomet Holdings Inc
For any enquires before buying, connect with us @ firstname.lastname@example.org
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +912064101019
Follow Us on LinkedIn: https://www.linkedin.com/company/orbis-research
Follow us on Twitter: https://twitter.com/orbisresearch
Like us on Facebook: https://www.facebook.com/OrbisResearch